A recent hantavirus outbreak aboard the MV Hondius cruise ship has sparked international concern, emphasising the urgent need for investment in novel antiviral treatments, according to GlobalData. The ship, which departed Argentina on 1 April, was denied docking near Cape Verde due to fears of viral spread and arrived in Tenerife, Spain, on 10 May. Passengers are now being repatriated and will spend at least a week in isolation to prevent further transmission.

The World Health Organisation (WHO) has confirmed seven hantavirus cases, including three fatalities, with two additional suspected cases. Symptoms reported include fever, gastrointestinal issues, pneumonia, acute respiratory distress syndrome, and shock. Anaelle Tannen, an Infectious Disease Analyst at GlobalData, noted that whilst the hantavirus outbreak is not expected to become a pandemic, it is classified as a level 3 emergency by the CDC, indicating active monitoring with low public risk.

Hantavirus, a rare virus transmitted by rodents, can cause severe lung disease in humans. The MV Hondius outbreak is linked to the Andes strain, primarily found in South America, which can spread between people in close contact. Tannen highlighted the increased transmission of infectious diseases due to climate change and globalisation, coupled with a lack of effective antiviral therapies.

Currently, there are no vaccines or specific antiviral treatments for hantavirus, with care focusing on symptom management. GlobalData's database indicates seven antiviral therapies in early development stages for hantavirus. Tannen emphasised the need for initiatives like the Pandemic Antiviral Discovery (PAD) to fund and accelerate antiviral research, making therapies globally accessible to combat future outbreaks

This story was selected and published by a human editor, with content adapted from original press material using AI tools. Spot an error? Report it here.